Evidence map›Paper›PMID 38536493›Full record

ArticlePflugers Archiv : European journal of physiology2024

Liraglutide versus pramlintide in protecting against cognitive function impairment through affecting PI3K/AKT/GSK-3β/TTBK1 pathway and decreasing Tau hyperphosphorylation in high-fat diet- streptozocin rat model.

Hoda M Moghazy, Nesreen G Abdelhaliem, Sherine Ahmed Mohammed, Asmaa Hassan, Amany Abdelrahman

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Pflugers Archiv : European journal of physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hoda M MoghazyDepartment of Physiology, Faculty of Medicine, Sohag University, Sohag, 82524, Egypt.
Nesreen G AbdelhaliemDepartment of Histology, Faculty of Medicine, Sohag University, Sohag, Egypt.
Sherine Ahmed MohammedDepartment of Histology, Faculty of Medicine, Sohag University, Sohag, Egypt.
Asmaa HassanDepartment of Physiology, Faculty of Medicine, Sohag University, Sohag, 82524, Egypt.
Amany AbdelrahmanDepartment of Physiology, Faculty of Medicine, Sohag University, Sohag, 82524, Egypt. amany_abdelhameed@med.sohag.edu.eg.ORCID 0000-0003-1909-242X
Sohag University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The American Diabetes Association guidelines (2021) confirmed the importance of raising public awareness of diabetes-induced cognitive impairment, highlighting the links between poor glycemic control and cognitive impairment. The characteristic brain lesions of cognitive dysfunction are neurofibrillary tangles (NFT) and senile plaques formed of amyloid-β deposition, glycogen synthase kinase 3 beta (GSK3β), and highly homologous kinase tau tubulin kinase 1 (TTBK1) can phosphorylate Tau proteins at different sites, overexpression of these enzymes produces extensive phosphorylation of Tau proteins making them insoluble and enhance NFT formation, which impairs cognitive functions. The current study aimed to investigate the potential contribution of liraglutide and pramlintide in the prevention of diabetes-induced cognitive dysfunction and their effect on the PI3K/AKT/GSK-3β/TTBK1 pathway in type 2 diabetic (T2D) rat model. T2D was induced by administration of a high-fat diet for 10 weeks, then injection of a single dose of streptozotocin (STZ); treatment was started with either pramlintide (200 μg/kg/day sc) or liraglutide (0.6 mg/kg/day sc) for 6 weeks in addition to the HFD. At the end of the study, cognitive functions were assessed by novel object recognition and T-maze tests. Then, rats were sacrificed for biochemical and histological assessment of the hippocampal tissue. Both pramlintide and liraglutide treatment revealed equally adequate control of diabetes, prevented the decline in memory function, and increased PI3K/AKT expression while decreasing GSK-3β/TTBK1 expression; however, liraglutide significantly decreased the number of Tau positive cells better than pramlintide did. This study confirmed that pramlintide and liraglutide are promising antidiabetic medications that could prevent associated cognitive disorders in different mechanisms.

Indexed as

Cognitive DysfunctionDiet, High-FatGlycogen Synthase Kinase 3 betaLiraglutidePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akttau ProteinsAnimalsDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Hypoglycemic AgentsIslet Amyloid PolypeptideMalePhosphorylationRatsRats, Sprague-DawleyGlycogen Synthase Kinase 3 betaHypoglycemic AgentsIslet Amyloid PolypeptideLiraglutidePhosphatidylinositol 3-KinasespramlintideProto-Oncogene Proteins c-aktStreptozocintau ProteinsGSK-3βLiraglutidePramlintideTTBK1

Identifiers

PMID38536493
PMCPMC11033245
OpenAlexW4393231857

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.